Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Melanoma 33Carcinoma, Renal Cell 11Neoplasms 6Neoplasm Metastasis 6Recurrence 4Multiple Myeloma 4Carcinoma, Hepatocellular 4Leukemia 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Mycosis Fungoides 2Lymphoma, Follicular 2Lymphoma 2Liver Neoplasms 2Kidney Neoplasms 2Hematologic Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Rituximab 301Cyclophosphamide 241Peripheral Blood Stem Cell Transplantation 115fludarabine phosphate 111Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 81Vincristine 79Prednisone 79Mycophenolic Acid 67Doxorubicin 62Whole-Body Irradiation 59Cyclosporine 59Bendamustine Hydrochloride 59Melphalan 57Tacrolimus 54Busulfan 52obinutuzumab 50fludarabine 50Cytarabine 49Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 33ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Introns × Clear all
NCT00577993 2020-11-16

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

M.D. Anderson Cancer Center

Phase 3 Completed
210 enrolled 14 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT00015912 2013-01-25

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡